KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Image-guided surgical navigation for inguinal sentinel lymph node procedures in vulvar cancer. PMID 41161157 · Int J Gynecol Cancer · 2025-Dec Study is a randomized feasibility trial in vulvar cancer but lacks required Phase III/IIIb status, drug intervention, and time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
High Virologic Suppression and Favorable Profiles of Two-Drug Antiretroviral Regimens in Africa: A Systematic Review of Current Evidence. PMID 41146527 · Clin Pharmacol Ther · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Variable Selection via Fused Sparse-Group Lasso Penalized Multi-state Models Incorporating Molecular Data. PMID 41146443 · Biom J · 2025-Dec The record is a methodological/statistical paper that applies a new algorithm to AML trial data, not a report of the trial's clinical efficacy results. While it references a Phase III RCT, the abstract does not contain the formal results of a time-to-event efficacy endpoint. Therefore, it is excluded as not being an original result report of trial efficacy.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID. PMID 41137844 · JACC Heart Fail · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta-Analysis. PMID 41137817 · Can J Cardiol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Integrating a pilot study and large trial into one adaptive design. PMID 41135812 · Contemp Clin Trials · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight. PMID 41135142 · Sleep Med · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials. PMID 41134450 · Dermatol Ther (Heidelb) · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Overlooked and underreported: A systematic review of quality of life in recent Phase III metastatic breast cancer trials. PMID 41130338 · J Cancer Policy · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. PMID 41127972 · Aliment Pharmacol Ther · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults. PMID 41123831 · CNS Drugs · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer. PMID 41116141 · Adv Ther · 2025-Dec The record describes a secondary, operational efficiency analysis (time-and-motion study) conducted alongside a phase 3 trial. It does not report the trial's primary or key secondary time-to-event efficacy outcomes (e.g., OS, PFS) and is therefore ineligible for a Kaplan-Meier digitization cohort focused on efficacy endpoints.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Microbiome and metabolome changes after fecal microbiota, live-jslm, administration are associated with health-related quality of life improvements. PMID 41115624 · Anaerobe · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study. PMID 41110828 · J Infect Chemother · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial. PMID 41109919 · Nat Med · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pre-Operative Resistance Training and Amino Acid Supplementation in Frail Patients With Gastrointestinal Cancer: A Randomized Clinical Trial. PMID 41108598 · Geriatr Gerontol Int · 2025-Dec The study is a randomized clinical trial in oncology patients, but it is not a Phase III/IIIb or Phase II/III trial, the intervention is non-drug-only (resistance training and amino acid supplementation), and the primary endpoints are postoperative complications and physical function, not time-to-event oncology efficacy endpoints like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus. PMID 41107649 · Clin Pharmacokinet · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials. PMID 41107641 · Pain Ther · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of comprehensive lifestyle interventions on plasma branched-chain amino acid concentrations: a randomized trial. PMID 41106729 · Am J Clin Nutr · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ten-year outcomes of 3D-conformal accelerated partial vs. whole breast irradiation after breast-conserving surgery: A randomized study from India. PMID 41106124 · Surg Oncol · 2025-Dec The study is a randomized oncology trial with time-to-event endpoints, but it does not involve a drug-containing intervention and the trial phase is not explicitly defined as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis. PMID 41085683 · Osteoporos Int · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. PMID 41083802 · Dermatol Ther (Heidelb) · 2025-Dec The record describes a protocol for a Phase 3 trial in alopecia areata (a non-malignant condition). The primary endpoint is a categorical response (SALT score ≤20), not a time-to-event endpoint like OS, PFS, or TTP. It does not report results; it is a protocol/design paper.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials. PMID 41066062 · Ophthalmol Ther · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial. PMID 41064908 · Allergy · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial. PMID 41062829 · Nat Med · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Endoscopic versus surgical gastroenterostomy for palliation of malignant gastric outlet obstruction (ENDURO): a randomised controlled trial. PMID 41061719 · Lancet Gastroenterol Hepatol · 2025-Dec The trial is a randomized, oncology study with a time-to-event primary endpoint, but it does not involve a drug-containing intervention (comparing two surgical/endoscopic procedures). Additionally, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial. PMID 41057084 · Radiother Oncol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of sacral nerve magnetic stimulation in preventing urinary retention after total hysterectomy: a randomised controlled trial. PMID 41051260 · J Obstet Gynaecol · 2025-Dec The study is a randomized controlled trial in a surgical population for gynecological malignancies, but it does not meet key eligibility criteria: (1) The intervention is sacral nerve magnetic stimulation (non-drug), not a drug-containing intervention. (2) The primary endpoint is incidence of postoperative urinary retention, not a time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or hazard ratio. (3) The phase of the trial is not specified as Phase III/IIIb or Phase II/III, and given the nature of the intervention (device/physical therapy), it is not a definitive oncology drug trial. The report is an original primary result but is excluded based on these fundamental mismatches with the cohort definition.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial. PMID 41047325 · Clin Ther · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial. PMID 41045868 · Semin Arthritis Rheum · 2025-Dec The study is a randomized, double-blind, placebo-controlled trial in rheumatoid arthritis, which is not an oncology (malignant neoplasm) indication. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials. PMID 41045349 · Neurol Ther · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. PMID 41043449 · Lancet Gastroenterol Hepatol · 2025-Dec 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L B
旧查询独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Beyond the first cut: Impact of repeat surgery versus boost on breast induration-A post hoc analysis from the DBCG HYPO & PBI trials. PMID 41043314 · Breast · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial. PMID 41036595 · Am J Hematol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ifupinostat: First Approval. PMID 41028651 · Drugs · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
VER-01 Shows Enhanced Gastrointestinal Tolerability, Superior Pain Relief, and Improved Sleep Quality Compared to Opioids in Treating Chronic Low Back Pain: A Randomized Phase 3 Clinical Trial. PMID 41028525 · Pain Ther · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evaluating clazosentan sodium for the treatment of aneurysmal subarachnoid hemorrhage. PMID 41024416 · Expert Rev Neurother · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. PMID 41023483 · Nat Med · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China: a post-hoc exploratory analysis of a phase III, randomized controlled trial. PMID 41020409 · J Dermatolog Treat · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial. PMID 41015742 · Urol Oncol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies. PMID 41014486 · Adv Ther · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized prospective trial comparing Bacillus Calmette-Guérin (BCG) RIVM and Russian strains in non-muscle invasive bladder cancer: Efficacy and side effects. PMID 41006133 · Urol Oncol · 2025-Dec The record meets criteria for being an original, randomized, oncology trial with time-to-event endpoints and a drug intervention. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, which is a required inclusion criterion. Therefore, it cannot be confirmed as eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early response to vunakizumab and its baseline predictors in patients with moderate-to-severe plaque psoriasis: a post hoc analysis of a phase-III trial. PMID 40995857 · J Dermatolog Treat · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation. PMID 40990091 · Am J Hematol · 2025-Dec Although the record mentions a Phase III registration trial (NCT01696084) and includes oncology, human, Phase III, time-to-event, and drug intervention signals, the specific report provided is a retrospective real-world study, not a report of the original randomized trial results. It lacks evidence of being a randomized trial itself.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Model-Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation. PMID 40990036 · CPT Pharmacometrics Syst Pharmacol · 2025-Dec The record is an oncology, human, randomized, phase III trial with a drug intervention, but it does not present original results for a time-to-event efficacy endpoint. The endpoints are pharmacokinetic exposure metrics, and the analysis is methodological (comparing modeling approaches), not the formal primary efficacy analysis of the trial.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study). PMID 40982097 · J Gastroenterol · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Efsubaglutide Alfa in "overrun" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation. PMID 40977363 · Diabetes Obes Metab · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Maintenance after first-line treatment for advanced soft tissue sarcoma. PMID 40975452 · Crit Rev Oncol Hematol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Quality of life results and survival outcomes in trials of immunotherapy in advanced cancers: A systematic review and meta-research study. PMID 40975451 · Crit Rev Oncol Hematol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. PMID 40974866 · J Autoimmun · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -